These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 22363068)
1. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ Oncologist; 2012; 17(3):321. PubMed ID: 22363068 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Oesterheld JE; Reed DR; Setty BA; Isakoff MS; Thompson P; Yin H; Hayashi M; Loeb DM; Smith T; Makanji R; Fridley BL; Wagner LM Pediatr Blood Cancer; 2020 Jul; 67(7):e28370. PubMed ID: 32386107 [TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Navid F; Willert JR; McCarville MB; Furman W; Watkins A; Roberts W; Daw NC Cancer; 2008 Jul; 113(2):419-25. PubMed ID: 18484657 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. Palmerini E; Jones RL; Marchesi E; Paioli A; Cesari M; Longhi A; Meazza C; Coccoli L; Fagioli F; Asaftei S; Grignani G; Tamburini A; Pollack SM; Picci P; Ferrari S BMC Cancer; 2016 Apr; 16():280. PubMed ID: 27098543 [TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. Mora J; Cruz CO; Parareda A; de Torres C J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011 [TBL] [Abstract][Full Text] [Related]
9. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. Leu KM; Ostruszka LJ; Shewach D; Zalupski M; Sondak V; Biermann JS; Lee JS; Couwlier C; Palazzolo K; Baker LH J Clin Oncol; 2004 May; 22(9):1706-12. PubMed ID: 15117993 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Lee EM; Rha SY; Lee J; Park KH; Ahn JH Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979 [TBL] [Abstract][Full Text] [Related]
11. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). Mora J; Castañeda A; Perez-Jaume S; Lopez-Pousa A; Maradiegue E; Valverde C; Martin-Broto J; Garcia Del Muro X; Cruz O; Cruz J; Martinez-Trufero J; Maurel J; Vaz MA; de Alava E; de Torres C Br J Cancer; 2017 Sep; 117(6):767-774. PubMed ID: 28787430 [TBL] [Abstract][Full Text] [Related]
12. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M; Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807 [TBL] [Abstract][Full Text] [Related]
14. Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study. Peretz Soroka H; Vora T; Noujaim J; Marcoux N; Cohen-Gogo S; Alcindor T; Holloway C; Rodrigues C; Karachiwala H; Alvi S; Lee U; Cheng S; Banerji S; Oberoi S; Feng X; Smrke A; Simmons C; Razak AA; Gupta AA Cancer Med; 2023 Sep; 12(18):18872-18881. PubMed ID: 37724607 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma. Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615 [TBL] [Abstract][Full Text] [Related]
16. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. He A; Qi W; Huang Y; Sun Y; Shen Z; Zhao H; Yang Y; Yao Y Int J Clin Oncol; 2013 Jun; 18(3):498-505. PubMed ID: 22534798 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital. Gosiengfiao Y; Reichek J; Woodman J; Ben-Ami T; Walterhouse D J Pediatr Hematol Oncol; 2012 Mar; 34(2):e63-5. PubMed ID: 22217487 [TBL] [Abstract][Full Text] [Related]
18. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Albertsson M; Johansson B; Friesland S; Kadar L; Letocha H; Frykholm G; Wagenius G Med Oncol; 2007; 24(4):407-12. PubMed ID: 17917090 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634 [TBL] [Abstract][Full Text] [Related]
20. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. Lee JA; Paik EK; Seo J; Kim DH; Lim JS; Yoo JY; Kim MS Jpn J Clin Oncol; 2016 Feb; 46(2):138-43. PubMed ID: 26685322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]